×

Contracts License Agreements

  • WASHINGTON, March 22- A U.S. Senate committee easily passed a bill on Wednesday to enable the nuclear regulator to license advanced nuclear reactors that backers say are safer than conventional plants and can help deal with a growing waste problem. The bill has brought together some Republicans eager to prevent the United States from falling behind China and...

  • WASHINGTON, March 22- A U.S. Senate committee easily passed a bill on Wednesday to enable the nuclear regulator to license advanced nuclear reactors that backers say are safer than conventional plants and can help deal with a growing waste problem. The bill has brought together some Republicans eager to prevent the United States from falling behind China and...

  • Dec 19- Swiss drugmaker Novartis on Monday said it signed a licensing deal to co-develop a fatty liver disease drug with Conatus Pharmaceuticals Inc, under which the small U.S. company will receive $50 million up front. Conatus shares rose to $4.20 in extended trading from a Nasdaq close at $1.96. Conatus has the option to co-commercialize emricasan in the...

  • Dec 19- Swiss drugmaker Novartis on Monday said it signed a licensing deal to co-develop a fatty liver disease drug with Conatus Pharmaceuticals Inc, under which the small U.S. company will receive $50 million up front. Conatus has the option to co-commercialize emricasan in the United States. It is estimated that NASH affects 3 percent to 5 percent of the U.S....

  • -Feb 2016: Investment of $42.5 million in Pronutria Biosciences, now Axcella Health, a specialist in developing medicines for disease caused by amino acid imbalance. -Sept 2015: Licensing agreement with Lipid Therapeutics for exclusive worldwide rights, except for Europe and Australia, to its experimental medicine for ulcerative colitis.

  • -Feb 2016: Investment of $42.5 million in Pronutria Biosciences, now Axcella Health, a specialist in developing medicines for disease caused by amino acid imbalance. -Sept 2015: Licensing agreement with Lipid Therapeutics for exclusive worldwide rights, except for Europe and Australia, to its experimental medicine for ulcerative colitis.

  • -Feb 2016: Investment of $42.5 million in Pronutria Biosciences, now Axcella Health, a specialist in developing medicines for disease caused by amino acid imbalance. -Sept 2015: Licensing agreement with Lipid Therapeutics for exclusive worldwide rights, except for Europe and Australia, to its experimental medicine for ulcerative colitis.

  • Pandora CFO: A new paradigm for music consumption

    Michael Herring, CFO at Pandora, discusses the music streaming company's outlook as well as how Pandora stacks up against competitors.